What is Curaleaf Holdings, Inc.'s (CURA.TO) StockRank?

MoatMap's StockRank for Curaleaf Holdings, Inc. (CURA.TO) is 43/100, with a Hold signal. This is a composite score combining Quality (41), Value (39), and Momentum (53) factor ranks across MoatMap's 20,000+ stock universe.

Does Curaleaf Holdings, Inc. have an economic moat?

Curaleaf Holdings, Inc. (CURA.TO) has a Quality factor score of 41/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Curaleaf Holdings, Inc. a buy, hold, or sell?

MoatMap's current signal for Curaleaf Holdings, Inc. (CURA.TO) is Hold, based on a StockRank of 43/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Curaleaf Holdings, Inc. in?

Curaleaf Holdings, Inc. (CURA.TO) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

CURA.TO

HOLDREMOVE

Curaleaf Holdings, Inc. · Healthcare · United States · $2.6B · Avg Vol: $2M/d

StockRank

P/E (TTM)

—

ROE

-8.7%

D/E

1.1x

Dividend %

—

Director Trades · 180d

−$569.1K →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Curaleaf is a major cannabis MSO but continues to face severe regulatory headwinds, lack of interstate commerce, and cash flow strains that violate our margin of safety principles.

COMPANY DESCRIPTION

Curaleaf Holdings, Inc. is a leading multi-state cannabis operator in the United States, engaged in the cultivation, processing, and retail distribution of cannabis products. The company's competitive moat is established through its massive retail footprint, vertically integrated supply chain, and strong brand portfolio across multiple legal state markets. It stands as a dominant market leader in the highly regulated and rapidly evolving global cannabis sector.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	1.3B	1.3B	1.3B	1.3B	-0.2%
EPS	-1.56	-1.17	-0.96	-1.05	—
Shares	301.8M	307.2M	312.7M	320.1M	+6.1%
Debt	928.7M	883.5M	853.8M	827.0M	-3.8%
Equity	1.3B	1.1B	861.2M	756.4M	-16.1%
Op CF	46.4M	75.3M	163.6M	137.7M	43.7%
Inv CF	-219.9M	-78.7M	-93.8M	-70.3M	—
Fin CF	41.8M	-67.0M	-54.2M	-73.5M	—

PRICE (1Y)+152.4%

SMA 50SMA 200

$9.62

RSI (14)

25.0

52W High

$14.77

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

0.9%46.2

ROE

-8.7%36.1

GP/Assets

30.3%65.8

Op. Margin

0.2%45.6

FCF/Assets

3.9%66.0

Piotroski

430.1

Int. Cover

0.2x36.9

D/E Ratio

1.15x12.7

Current Ratio

1.56x27.0

Value

P/E (TTM)

—N/A

EV/EBITDA

15.9x40.4

P/FCF

31.7x36.3

P/B

2.3x54.0

P/S

2.1x66.8

Div Yield

—N/A

Momentum

52W High %

65%45.8

RS 6M

9%78.8

SMA 50/200

1.22x90.4

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-53%8.5

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$2.6B

P/E (Forward)

-15.3x

Gross Margin

49.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CURA.TO are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
CURA.TO	Curaleaf Holdings, Inc.(you)	$2.6B	43	HOLD
AMLX	Amylyx Pharmaceuticals, Inc.	$1.8B	35	HOLD
BIOA	BioAge Labs, Inc.	$959M	44	HOLD
HROW	Harrow, Inc.	$1.5B	32	SELL
SUPN	Supernus Pharmaceuticals, Inc.	$2.6B	64	HOLD
XERS	Xeris Biopharma Holdings, Inc.	$1.2B	50	HOLD
PBH	Prestige Consumer Healthcare Inc.	$2.2B	75	BUY
ESPR	Esperion Therapeutics, Inc.	$814M	29	SELL
ETON	Eton Pharmaceuticals, Inc.	$888M	58	HOLD
LQDA	Liquidia Corporation	$6.5B	64	HOLD

Peer medians: ROE -22.3% · P/E 25.1x · Gross margin 44.2%

Curaleaf Holdings, Inc. (CURA.TO) — Stock Score Summary

Curaleaf Holdings, Inc. (CURA.TO) has a MoatMap StockRank of 43/100 based on Quality (41/100), Value (39/100), and Momentum (53/100) factor scores. The current signal is HOLD. Curaleaf is a major cannabis MSO but continues to face severe regulatory headwinds, lack of interstate commerce, and cash flow strains that violate our margin of safety principles.

Key Financial Metrics

Price	$9.62
Market Cap	$2.6B
P/E (Forward)	-15.31
Price/Book	2.27
Return on Equity	-8.7%
Return on Invested Capital	0.9%
Debt/Equity	114.54
Gross Margin	49.2%
Operating Margin	0.2%
Revenue Growth	5.7%
Free Cash Flow	$82M

Curaleaf Holdings, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Curaleaf Holdings, Inc.’s (CURA.TO) StockRank?: MoatMap’s StockRank for Curaleaf Holdings, Inc. (CURA.TO) is 43/100, with a Hold signal. It is a composite of Quality (41), Value (39), and Momentum (53) factor ranks across MoatMap’s 20,000+ stock universe.
Does Curaleaf Holdings, Inc. have an economic moat?: Curaleaf Holdings, Inc. (CURA.TO) has a Quality factor score of 41/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Curaleaf Holdings, Inc. a buy, hold, or sell?: MoatMap’s current signal for Curaleaf Holdings, Inc. (CURA.TO) is Hold, based on a StockRank of 43/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Curaleaf Holdings, Inc. in?: Curaleaf Holdings, Inc. (CURA.TO) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).